Filter Results:
(994)
Show Results For
- All HBS Web
(994)
- People (4)
- News (257)
- Research (615)
- Events (9)
- Multimedia (24)
- Faculty Publications (398)
Show Results For
- All HBS Web
(994)
- People (4)
- News (257)
- Research (615)
- Events (9)
- Multimedia (24)
- Faculty Publications (398)
- 2019
- Chapter
Characterizing the Drug Development Pipeline for Precision Medicines
By: Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
BOOK ABSTRACT: Personalized and precision medicine (PPM)—the targeting of therapies according to an individual’s genetic, environmental, or lifestyle characteristics—is becoming an increasingly important approach in health care treatment and prevention. The advancement... View Details
Chandra, Amitabh, Craig Garthwaite, and Ariel Dora Stern. "Characterizing the Drug Development Pipeline for Precision Medicines." Chap. 5 in Economic Dimensions of Personalized and Precision Medicine, edited by Ernest R. Berndt, Dana P. Goldman, and John W. Rowe, 115–158. University of Chicago Press, 2019.
- November 23, 2012
- Article
Holiday Discounts Are a Dangerous Drug
By: Marco Bertini
Bertini, Marco. "Holiday Discounts Are a Dangerous Drug." Harvard Business Review Digital Articles (November 23, 2012).
- April 1989
- Supplement
Novel Combination of Two Drugs (C)
Herzlinger, Regina E. "Novel Combination of Two Drugs (C)." Harvard Business School Supplement 189-170, April 1989.
- April 1989
- Supplement
Novel Combination of Two Drugs (B)
Herzlinger, Regina E. "Novel Combination of Two Drugs (B)." Harvard Business School Supplement 189-169, April 1989.
- 12 Jun 2018
- Research & Ideas
In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation?
ubingruo New research finds that large pharmaceutical companies, typically conservative in their pursuit of novel drug development, are more willing to undertake radical innovation after receiving an unexpected cash windfall. The... View Details
- 13 Oct 2016
- News
Drug Coupons: Helping a Few at the Expense of Everyone
- 18 Feb 2016
- News
Challenge Aims to Speed Drug Trials Process
clinical trials process. Today, it takes at least 10 years and billions of dollars for one FDA-approved drug to move from research labs to medicine cabinets. Precision medicine will bring faster innovation, targeted medicine, and better... View Details
- March 1989 (Revised August 1989)
- Case
GI Wars: Tums vs. Rolaids—Positioning Over-the-Counter Drugs
Herzlinger, Regina E. "GI Wars: Tums vs. Rolaids—Positioning Over-the-Counter Drugs." Harvard Business School Case 189-118, March 1989. (Revised August 1989.)
- Web
2.3.1 Drug & Alcohol Policy | MBA
2.3.1 Drug & Alcohol Policy Harvard Business School’s policy on drugs and alcohol—adapted from and in accordance with other similar policies at Harvard University—reflects our concern for the health and... View Details
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details
Keywords: Health Care and Treatment; Strategic Planning; Competition; Patents; Innovation and Invention; Pharmaceutical Industry; Biotechnology Industry; United States
Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)
- April 2010
- Case
Metabical: Pricing, Packaging, and Demand Forecasting Recommendations for a New Weight Loss Drug
By: John A. Quelch and Heather Beckham
Metabical is a new weight loss drug from Cambridge Sciences Pharmaceuticals intended for moderately overweight individuals. In anticipation of final FDA approval, the senior director of marketing, Barbara Printup, prepares for the product launch and must make several... View Details
Keywords: Return On Investment; Forecasting; Pricing Policies; Demand Planning; Marketing Strategy; Price; Consumer Behavior; Investment Return; Forecasting and Prediction; Product Launch; Planning; Brands and Branding; Pharmaceutical Industry
Quelch, John A., and Heather Beckham. "Metabical: Pricing, Packaging, and Demand Forecasting Recommendations for a New Weight Loss Drug." Harvard Business School Brief Case 104-183, April 2010.
- February 14, 2019
- Other Article
We Should Treat Algorithms like Prescription Drugs
By: Andy Coravos, Irene Chen, Ankit Gordhandas and Ariel Dora Stern
Coravos, Andy, Irene Chen, Ankit Gordhandas, and Ariel Dora Stern. "We Should Treat Algorithms like Prescription Drugs." Quartz (February 14, 2019).
- July – August 2000
- Article
Drug Industry Mergers Won't Necessarily Benefit R&D
Henderson, Rebecca M. "Drug Industry Mergers Won't Necessarily Benefit R&D." Research-Technology Management 43, no. 4 (July–August 2000): 10–11.
- June 2005
- Article
A Rising Drug Industry: Pharmaceuticals since 1870
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "A Rising Drug Industry: Pharmaceuticals since 1870." Chemical and Engineering News (June 2005), 28–42.
- 23 Aug 2008
- News
Healthy people more willing to take drugs
- October 2024
- Article
Medicare Part D Protected-Class Policy Is Associated with Lower Drug Rebates
By: Pragya Kakani, Michael Anne Kyle, Amitabh Chandra and Luca Maini
Medicare Part D does not allow plans to exclude drugs in six protected classes from their formularies, which may limit plans’ ability to negotiate rebates and lead to higher spending. We estimated the association between protected-class status, US-level estimated... View Details
Keywords: Insurance; Health Care and Treatment; Governing Rules, Regulations, and Reforms; United States
Kakani, Pragya, Michael Anne Kyle, Amitabh Chandra, and Luca Maini. "Medicare Part D Protected-Class Policy Is Associated with Lower Drug Rebates." Health Affairs 43, no. 10 (October 2024): 1420–1427.
- November 2009 (Revised March 2010)
- Case
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details
Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Marketing Strategy; Product Positioning; Genetics; Biotechnology Industry; Europe; United States
Hamermesh, Richard G., Raju Kucherlapati, and Rachel Gordon. "Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story." Harvard Business School Case 810-066, November 2009. (Revised March 2010.)
- February 1993 (Revised August 1995)
- Case
Medicare Payment for Drugs and Medical Devices
Keywords: Health Care and Treatment; Business and Government Relations; Medical Devices and Supplies Industry; Health Industry; Pharmaceutical Industry
Herzlinger, Regina E. "Medicare Payment for Drugs and Medical Devices." Harvard Business School Case 193-099, February 1993. (Revised August 1995.)
- July 2019
- Article
The Impact of Price Regulation on the Availability of New Drugs in Germany
By: Ariel Dora Stern, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim and Ameet Sarpatwari
The 2011 German Pharmaceutical Market Restructuring Act (“AMNOG”) subjected branded, non-rare disease drugs to price regulation based on an assessment of their clinical benefit. Assessment outcomes range from “major added benefit” to “less benefit than the appropriate... View Details
Keywords: Regulation; Pharmaceuticals; Healthcare; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Germany
Stern, Ariel Dora, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim, and Ameet Sarpatwari. "The Impact of Price Regulation on the Availability of New Drugs in Germany." Health Affairs 38, no. 7 (July 2019): 1182–1187.